A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer

NCT03498716 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

2199

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated by the sponsor following interim analysis as the primary endpoint of iDFS crossed the pre-specified futility boundary of hazard ratio \> 1 in the Intent-to-Treat (ITT) population.

Conditions

Triple Negative Breast Cancer

Interventions

DRUG: Atezolizumab
DRUG: Paclitaxel
DRUG: Dose-dense Doxorubicin or dose-dense Epirubicin
DRUG: Cyclophosphamide

Sponsor

Hoffmann-La Roche

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]